pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
MOUNJARO · news · pharmadog
← back to MOUNJARO
News mentioning MOUNJARO
69
stories
Jul 21, 26
STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
stat
Jul 17, 26
Compounders maintain a firm grip on the GLP-1 market
biopharma dive
Jul 16, 26
Opinion: The growing fang-to-pharmacy pipeline
stat
Jul 15, 26
STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more
stat
Jul 9, 26
Opinion: Who benefits from classifying obesity as a disease?
stat
Jul 7, 26
Kailera says obesity pill succeeds in late-stage trial in China
biopharma dive
Jul 7, 26
Ebola outbreak exposes a fractured outbreak response system
stat
Jul 6, 26
STAT+: Online GLP-1 prescriptions are often fast, easy — and low on clinical oversight
stat
Jul 2, 26
STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more
stat
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 18, 26
What’s next for GLP-1 weight loss drugs?
stat
Jun 11, 26
STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
stat
Jun 8, 26
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
biopharma dive
Jun 7, 26
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
stat
Jun 6, 26
STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
stat
Jun 3, 26
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
stat
Jun 2, 26
Eli Lilly issues data sharing ultimatum to 340B hospitals
biopharma dive
Jun 1, 26
STAT+: Medicare’s mum on GLP-1s, and Massachusetts sues United
stat
Jun 1, 26
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
stat
Jun 1, 26
CDC says containing the spread of Ebola is top priority
stat
Jun 1, 26
STAT+: Medicare still won’t say how much covering obesity drugs will cost
stat
May 29, 26
Which vaccines will curb the Ebola outbreak? WHO debates
stat
May 29, 26
Opinion: I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’
stat
May 28, 26
Lilly obesity meds Foundayo and Zepbound to gain CVS coverage
endpoints
May 28, 26
CVS obesity drug deal puts Lilly on equal footing with Novo
biopharma dive
May 13, 26
Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss
biopharma dive
May 13, 26
STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
stat
May 12, 26
Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance options
endpoints
May 12, 26
STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
stat
May 8, 26
Lilly to invest extra $4.5B across Indiana manufacturing
biopharma dive
← prev
page 2 of 3
next →
